Terms: = Breast cancer AND FOXP3, AIID, DIETER, IPEX, JM2, PIDX, XPID AND Diagnosis
20 results:
1. Components of the tumor immune microenvironment based on m-IHC correlate with prognosis and subtype of triple-negative breast cancer.
Lin L; Li H; Wang X; Wang Z; Su G; Zhou J; Sun S; Ma X; Chen Y; You C; Gu Y
Cancer Med; 2023 Dec; 12(24):21639-21650. PubMed ID: 38059408
[TBL] [Abstract] [Full Text] [Related]
2. Dormant tumors circumvent tumor-specific adaptive immunity by establishing a Treg-dominated niche via DKK3.
Trotter TN; Dagotto CE; Serra D; Wang T; Yang X; Acharya CR; Wei J; Lei G; Lyerly HK; Hartman ZC
JCI Insight; 2023 Nov; 8(22):. PubMed ID: 37847565
[TBL] [Abstract] [Full Text] [Related]
3. Matrix Metalloproteinase-9 Expression Is Associated with the Absence of Response to Neoadjuvant Chemotherapy in Triple-Negative breast cancer Patients.
Lejeune M; Reverté L; Gallardo N; Sauras E; Bosch R; Mata D; Roso A; Petit A; Peg V; Riu F; García-Fontgivell J; Relea F; Vieites B; de la Cruz-Merino L; Arenas M; Rodriguez V; Galera J; Korzynska A; Plancoulaine B; Álvaro T; López C
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511057
[TBL] [Abstract] [Full Text] [Related]
4. PROGNOSTIC ROLE OF RESIDUAL TUMOR FEATURES IN HER2-NEGATIVE breast cancer.
Sivak LA; Lyalkin SA; Verevkina NO; Shipko AF
Exp Oncol; 2022 Nov; 44(3):222-226. PubMed ID: 36325708
[TBL] [Abstract] [Full Text] [Related]
5. Tumour-infiltrating CD4-, CD8- and foxp3-positive immune cells as predictive markers of mortality in BRCA1- and BRCA2-associated breast cancer.
Jørgensen N; Hviid TVF; Nielsen LB; Sønderstrup IMH; Eriksen JO; Ejlertsen B; Gerdes AM; Kruse TA; Thomassen M; Jensen MB; Lænkholm AV
Br J Cancer; 2021 Nov; 125(10):1388-1398. PubMed ID: 34365471
[TBL] [Abstract] [Full Text] [Related]
6. Neoadjuvant chemotherapy alters the balance of effector to suppressor immune cells in advanced ovarian cancer.
Leary A; Genestie C; Blanc-Durand F; Gouy S; Dunant A; Maulard A; Drusch F; Cheaib B; Michels J; Bentivegna E; LeFormal A; Mesnage S; Morice P; Pautier P; Khairallah AS
Cancer Immunol Immunother; 2021 Feb; 70(2):519-531. PubMed ID: 32852603
[TBL] [Abstract] [Full Text] [Related]
7. The number of foxp3-positive tumor-infiltrating lymphocytes in patients with synchronous bilateral breast cancer.
Goto R; Hirota Y; Aruga T; Horiguchi S; Miura S; Nakamura S; Takimoto M
Breast Cancer; 2020 Jul; 27(4):586-593. PubMed ID: 31933123
[TBL] [Abstract] [Full Text] [Related]
8. Impact of a Pre-Operative Exercise Intervention on breast cancer Proliferation and Gene Expression: Results from the Pre-Operative Health and Body (PreHAB) Study.
Ligibel JA; Dillon D; Giobbie-Hurder A; McTiernan A; Frank E; Cornwell M; Pun M; Campbell N; Dowling RJO; Chang MC; Tolaney S; Chagpar AB; Yung RL; Freedman RA; Dominici LS; Golshan M; Rhei E; Taneja K; Huang Y; Brown M; Winer EP; Jeselsohn R; Irwin ML
Clin Cancer Res; 2019 Sep; 25(17):5398-5406. PubMed ID: 31018921
[TBL] [Abstract] [Full Text] [Related]
9. Minimally Invasive Intact Excision of High-Risk breast Lesions and Small breast cancers: The Intact Percutaneous Excision (ipex) Registry.
Whitworth P; Schonholz S; Phillips R; Robertson Y; Ruiz A; Winchester S; Graham C; Simpson J; Wernecke C
Ann Surg Oncol; 2019 Apr; 26(4):954-960. PubMed ID: 30756327
[TBL] [Abstract] [Full Text] [Related]
10. Prognostic Role and Clinical Association of Tumor-Infiltrating Lymphocyte, Programmed Death Ligand-1 Expression with Neutrophil-Lymphocyte Ratio in Locally Advanced Triple-Negative breast cancer.
Lee J; Kim DM; Lee A
Cancer Res Treat; 2019 Apr; 51(2):649-663. PubMed ID: 30064200
[TBL] [Abstract] [Full Text] [Related]
11. Composite analysis of immunological and metabolic markers defines novel subtypes of triple negative breast cancer.
Adams TA; Vail PJ; Ruiz A; Mollaee M; McCue PA; Knudsen ES; Witkiewicz AK
Mod Pathol; 2018 Feb; 31(2):288-298. PubMed ID: 28984302
[TBL] [Abstract] [Full Text] [Related]
12. Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive breast cancer: A Secondary Analysis of a Randomized Clinical Trial.
Liu S; Chen B; Burugu S; Leung S; Gao D; Virk S; Kos Z; Parulekar WR; Shepherd L; Gelmon KA; Nielsen TO
JAMA Oncol; 2017 Nov; 3(11):e172085. PubMed ID: 28750133
[TBL] [Abstract] [Full Text] [Related]
13. [CD8 and foxp3 expression in stromal tumor-infiltrating lymphocytes of triple-negative breast carcinomas: a clinicopathologic study].
Pan BJ; Ping GQ; Zhang WM; Wang C; Li HX; Zhang ZH
Zhonghua Bing Li Xue Za Zhi; 2016 Aug; 45(8):540-4. PubMed ID: 27510779
[TBL] [Abstract] [Full Text] [Related]
14. Presence of circulating Her2-reactive CD8 + T-cells is associated with lower frequencies of myeloid-derived suppressor cells and regulatory T cells, and better survival in older breast cancer patients.
Bailur JK; Gueckel B; Derhovanessian E; Pawelec G
Breast Cancer Res; 2015 Mar; 17(1):34. PubMed ID: 25849846
[TBL] [Abstract] [Full Text] [Related]
15. Study of circulating antibodies against CD25 and foxp3 in breast cancer.
Liu T; Song YN; Shi QY; Liu Y; Bai XN; Pang D
Tumour Biol; 2014 Apr; 35(4):3779-83. PubMed ID: 24347486
[TBL] [Abstract] [Full Text] [Related]
16. Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study.
Cimino-Mathews A; Ye X; Meeker A; Argani P; Emens LA
Hum Pathol; 2013 Oct; 44(10):2055-63. PubMed ID: 23701942
[TBL] [Abstract] [Full Text] [Related]
17. Definitive diagnosis for high-risk breast lesions without open surgical excision: the Intact Percutaneous Excision Trial (IPET).
Whitworth PW; Simpson JF; Poller WR; Schonholz SM; Turner JF; Phillips RF; Johnson JM; McEachin FD
Ann Surg Oncol; 2011 Oct; 18(11):3047-52. PubMed ID: 21947585
[TBL] [Abstract] [Full Text] [Related]
18. Intact Percutaneous Excision (ipex) for Definitive diagnosis of High-Risk breast Lesions.
Whitworth PW
Ann Surg Oncol; 2011 Oct; 18(11):3095. PubMed ID: 21904961
[TBL] [Abstract] [Full Text] [Related]
19. Upregulation of human leukocyte antigen-G expression and its clinical significance in ductal breast cancer.
Chen HX; Lin A; Shen CJ; Zhen R; Chen BG; Zhang X; Cao FL; Zhang JG; Yan WH
Hum Immunol; 2010 Sep; 71(9):892-8. PubMed ID: 20547193
[TBL] [Abstract] [Full Text] [Related]
20. foxp3 germline polymorphisms are not associated with risk of breast cancer.
Raskin L; Rennert G; Gruber SB
Cancer Genet Cytogenet; 2009 Apr; 190(1):40-2. PubMed ID: 19264232
[TBL] [Abstract] [Full Text] [Related]
